Aspirin (Antiplatelet — ACS/PCI)
Brand names: Disprin, Caprin
Low-dose aspirin is an antiplatelet used in acute coronary syndromes and for long-term secondary prevention of cardiovascular events; it is not used for routine primary prevention because the bleeding risk usually outweighs benefit.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKDirections drink a full glass of water with each dose adults and children 12 years and over: take 4 to 8 tablets every 4 hours not to exceed 48 tablets in 24 hours unless directed by a doctor children under 12 years: consult a doctor
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2024-04-16. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Clinical monograph
How it works
Aspirin irreversibly acetylates cyclo-oxygenase-1 in platelets, blocking thromboxane A2 production and platelet aggregation for the platelet's lifespan.
Prescribing in practice
- A higher loading dose is given in ACS, followed by a low maintenance dose.
- Gastrointestinal bleeding risk rises with age and with other antithrombotics, NSAIDs or steroids; consider gastroprotection in higher-risk patients.
- Avoid in active peptic ulceration and in children (Reye's syndrome risk), and use caution in aspirin-sensitive asthma.
Monitoring
No routine monitoring; review for dyspepsia or bleeding, particularly in older patients and with co-prescribed antithrombotics.
Counselling the patient
- Take it with or after food.
- Report black stools, vomiting blood, or persistent indigestion.
- Do not stop suddenly after a cardiac event without advice.
Evidence & guidelines
Aspirin is standard in ACS and long-term secondary prevention; routine primary-prevention use is no longer recommended for most people.
Reference: ESC STEMI Guidelines 2023; ESC NSTE-ACS Guidelines 2020; NICE NG185 (ACS); SPC Aspirin; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- DAPT Score · Coronary Artery Disease
- ARC-HBR Criteria for High Bleeding Risk in PCI · Coronary Artery Disease
- PRECISE-DAPT Score for Bleeding on DAPT · Coronary Artery Disease
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- DAPT Decision Tool (Ticagrelor vs Clopidogrel) · Antiplatelet Therapy
- Pericarditis Diagnostic Score (Imazio Criteria) · Pericardial Disease
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines